急性淋巴细胞白血病中祖先特异性复发风险的遗传学
在儿童肿瘤协作组AALL0232试验的2225例急性淋巴细胞白血病患儿中,研究胚系遗传变异对复发的影响,发现302个与复发相关的SNP及715个祖先特异性SNP,部分与抗白血病药物清除或耐药相关,并可在独立队列中重复;加入4个SNP后黑人和西班牙裔祖先的不良风险减弱。
要点
- 在2225例AALL0232试验患儿中,识别出302个校正治疗和祖先后的复发相关胚系SNP及715个祖先特异性复发相关SNP。
- 224个SNP与快速药物清除或耐药相关,32个在独立队列中重复。
- 加入4个最强复发相关SNP后,黑人祖先风险从HR=2.32降至HR=1.07,西班牙裔从HR=1.7降至HR=1.31。
核心结论
- 遗传性遗传变异 contributes to race-specific and treatment-specific relapse risk in childhood ALL.
研究设计与样本
- 研究纳入2225例在儿童肿瘤协作组AALL0232试验中治疗的儿童急性淋巴细胞白血病患者,评估胚系遗传因素对复发的贡献。
主要发现
- 在2225例患儿中识别出302个校正治疗和祖先后的复发相关胚系单核苷酸多态性(SNP),以及715个以祖先特异性方式与复发相关的额外SNP。
- 224个SNP与快速药物清除或耐药相关,其中32个在独立临床队列中重复。
- 黑人祖先的不良风险:未纳入SNP的模型HR=2.32(P=2.27×10-4),纳入SNP的模型HR=1.07(P=0.79);西班牙裔祖先:未纳入SNP的模型HR=1.7(P=8.23×10-5),纳入SNP的模型HR=1.31(P=0.065)。
- 与天冬酰胺酶耐药或过敏相关的复发SNP在更强天冬酰胺酶治疗组中富集:Capizzi-甲氨蝶呤组54个中20个 vs 大剂量甲氨蝶呤组54个中8个(P=0.015)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The causes of individual relapses in children with acute lymphoblastic leukemia (ALL) remain incompletely understood. We evaluated the contribution of germline genetic factors to relapse in 2225 children treated on Children's Oncology Group trial AALL0232. We identified 302 germline single-nucleotide polymorphisms (SNPs) associated with relapse after adjusting for treatment and ancestry and 715 additional SNPs associated with relapse in an ancestry-specific manner. We tested for replication of these relapse-associated SNPs in external data sets of antileukemic drug pharmacokinetics and pharmacodynamics and an independent clinical cohort. 224 SNPs were associated with rapid drug clearance or drug resistance, and 32 were replicated in the independent cohort. The adverse risk associated with black and Hispanic ancestries was attenuated by addition of the 4 SNPs most strongly associated with relapse in these populations (for blacks: model without SNPs hazard ratio (HR)=2.32, P=2.27 × 10-4, model with SNPs HR=1.07, P=0.79; for Hispanics: model without SNPs HR=1.7, P=8.23 × 10-5, model with SNPs HR=1.31, P=0.065). Relapse SNPs associated with asparaginase resistance or allergy were overrepresented among SNPs associated with relapse in the more asparaginase intensive treatment arm (20/54 in Capizzi-methorexate arm vs 8/54 in high-dose methotrexate arm, P=0.015). Inherited genetic variation contributes to race-specific and treatment-specific relapse risk.
引用
- Karol SE, Larsen E, Cheng C, et al. Genetics of ancestry-specific risk for relapse in acute lymphoblastic leukemia. Leukemia. 2017. PMID: 28096535. doi:10.1038/leu.2017.24
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。